VISIT US AT BOOTH #3043 Envisioning a chemo-free, oral monotherapy treatment future for patients with CLL/SLL A Phase 2 Study of Duvelisib Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated with a Bruton's Tyrosine Kinase Inhibitor (BTKi) Study end points CLL/SLL patients, R/R or intolerant to prior BTKi (N = ~50) Duvelisib 25 mg BID * Primary: ORR * Secondary: - DOR, DCR, PFS, Safety - Mutation-activity correlations, MRD and immune response assessments Trial Design Details Key inclusion criteria: * ≥1 prior anti-cancer therapy * BTKi treatment must be the last prior anti-cancer therapy and patients meet at least one of the criteria below: a) Progressive disease (PD) while receiving or within 6 months after completing BTKi therapy b) Discontinued a BTKi therapy due to BTKi treatment-related intolerance Key exclusion criterion: * Richter's transformation or prolymphocytic leukemia Enrolling 2018: Multiple U.S. sites Contact medicalaffairs@verastem.com for more information Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. For more information, please visit www.verastem.com or contact us at medaffairs@verastem.com Duvelisib is an investigational agent available for clinical trial use only. Safety and efficacy have not been established.